| Clinical data | |
|---|---|
| Other names | Deu-mitragynine; Deuterated mitragynine; KUR-101; KUR101 |
| Routes of administration | Oral[1][2] |
| Drug class | Atypicalμ-opioid receptoragonist;Analgesic |
Deuterated mitragynine (developmental code nameKUR-101) is an atypicalμ-opioid receptoragonist anddeuteratedanalogue ofmitragynine (found inkratom) which is under development for the treatment ofacute pain andopioid-related disorders.[2][3][1][4][5] It is takenby mouth.[1][2] Deumitragynine is said to haveanalgesic effects.[4] The drug is being developed byATAI Life Sciences and Kures.[2][3][1][5] As of December 2022, it is inphase 1clinical trials for acute pain and opioid-related disorders.[2][3][1]
Table 1. Biochemical structures, mechanisms, and receptor functions of twenty psychoceutical drugs: [...] Drug Name: Deu-mitragynine (Kratom) [...] Chemical Structure: *. Target Type: Opioid Receptor. Method of Action: Deu-mitragynine acts as a mu-opioid (MOR) agonist with the ability to interact with G-protein coupled receptors, resulting in its analgesic effects. Deu-mitragynine has been shown to exhibit opioid-receptor-dependent analgesic effects and G-protein-based agonists of MOR. Citations: Atai Life Sciences [28] Shukla et al. [29] [...] The drugs targeting opioid receptors, deu-mitragynine (a major alkaloid component of kratom [28]) and salvinorin A (a non-alkaloidal component of Salvia divinorum [30]), regulate pathways initiated by G-proteins, while also stimulating other mechanisms, such as the beta-arrestin and ERK/MAPK pathways. Kratom, a mu-opioid receptor (MOR) agonist with low potency, has been demonstrated to emit 'atypical' opioid effects (no respiratory depression, emesis, or shortness of breath in animal models) through G-protein agonistic activity and limited recruitment of beta-arrestin after opioid receptor-dependent activation [28,29]. Studies with rodent models alternatively suggest mitragynine and its derivatives do not directly activate opioid receptors [29], which brings into question how the drug initiates the activity of MORs to deliver analgesic effects.
We note that the FDA has recommended development of new drug applications for potential kratom-derived products, including by its botanical drug development pathway. At the time of this writing, we are aware of at least one such effort that has been made public (e.g., atai Life Sciences, 2022; Sparian Biosciences, 2023). [...] Atai Life Sciences (2022). Atai life sciences announces results from the kures therapeutics Phase 1 trial of KUR-101.;"atai Life Sciences Announces Results from the Kures Therapeutics Phase 1 Trial of KUR-101".atai Life Sciences. 23 December 2022. Retrieved13 February 2024.
 | Thispsychoactive drug-related article is astub. You can help Wikipedia byadding missing information. |
